Valentina M. Vorobyeva

Valentina M. Vorobyeva

Auto-generated profile, based on publicly available information

Valentina M. Vorobyeva

Altai State Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2024 in Clinical Dentistry (Russia)
Verified
Journal Article
Open access
PDF file
ОШО.е. Шишкина
О.е. Шишкина
ВВВ.м. Воробьева
В.м. Воробьева
ОМО.н. Мазко
О.н. Мазко
НСН.в. Семенникова
Н.в. Семенникова
ЕБЕ.а. Берент
Е.а. Берент
КЛК.с. Лоор
К.с. Лоор
Использование заменителей слюны — ключевая концепция лечения ксеростомии, направленного на уменьшение симптомов сухости во рту и поддержание здоровья полости рта. На основании справочных данных и данных научной литературы проведен анализ имеющихся на рынке средств для заместительной терапии при ксеростомии и их основных ингредиентов. Дана характеристика основных компонентов саливопротекторов с учетом их функций в составе гелей и спреев для симптоматической терапии ксеростомии: солей-электролитов, ферментов, муцина, полимеров-гидроколлоидов, влагоудерживающих многоатомных спиртов, сахарозаменителей, фитопрепаратов. Ограниченное наличие на рынке стоматологических средств — саливозаменителей преимущественно зарубежного производства, особенно в условиях экономической изоляции, с учетом роста данной патологии обусловливает актуальность разработки отечественных средств для лечения ксеростомии. Обоснована необходимость разработки саливозаменителей в связи с распространенностью данного синдрома, тенденцией к росту из-за демографического старения населения и необходимости приема препаратов ксерогенного действия для терапии системных заболеваний. The use of saliva substitutes is a key concept in the treatment of xerostomia, aimed at reducing the symptoms of dry mouth and maintaining oral health. Based on reference data and scientific literature, an analysis of the available products for replacement therapy for xerostomia and their main ingredients was carried out. The characteristics of the main components of salivary protectors are given, taking into account their functions in the composition of gels and sprays for the symptomatic therapy of xerostomia: electrolyte salts, enzymes, mucin, hydrocolloid polymers, water-retaining polyhydric alcohols, sugar substitutes, and herbal preparations. The limited availability of dental products on the market — salivary substitutes, mainly of foreign manufacture, especially in conditions of economic isolation, taking into account the growth of this pathology, determines the relevance of developing domestic products for the treatment of xerostomia. The necessity of developing salivary substitutes is substantiated in connection with the prevalence of this syndrome, the tendency to increase due to demographic aging of the population and the need to take xerogenic drugs for the treatment of systemic diseases.

1 January 2024 in Bulletin of Medical Science
Verified
Journal Article
Open access
AUAltai State Medical University
Altai State Medical University
OMOlesya N. Mazko
Olesya N. Mazko
VVValentina M. Vorobyeva
Valentina M. Vorobyeva
OSOksana E. Shishkina
Oksana E. Shishkina
NSNina V. Semennikova
Nina V. Semennikova
OSOlga V. Shoykhet
Olga V. Shoykhet
Introduction. In clinical practice, xerostomia, or dry mouth (ICD 10 - K 11.7), is a chronic disease that usually develops against a background of hyposalivation, when salivary secretion is reduced to 50-60%, but can also occur with normal salivary secretion, but with a violation of ratio of components of the salivary gland secretion. The causes of xerostomia are due to many medical problems and factors. Xerostomia syndrome complicates the development of dental diseases, leads to tooth loss, which ultimately significantly reduces the quality of life of patients. Regardless of the cause of the development of xerostomia, patients need substitution therapy with artificial saliva preparations. To expand the range of products for dental practice and import substitution, we have developed a saliva substitute composition in the form of a moisturizing gel based on mucoadhesive polymers. One of the requirements for new drug formulations in the context of preclinical studies is the absence of “acute” and chronic toxicity. Objective. To evaluate the toxicity of antixerostomy moisturizing gel by single administration in mice and rats. Materials and methods. The object of the study was a gel composition of saliva substitute based on mucoadhesive polymers and a complex of biologically active substances, including lysozyme, pyridoxine hydrochloride, and tocopherol acetate. As part of preclinical drug studies, the toxicity of the experimental gel was studied during single administration. During the experiment, the drug was administered intragastrically through a probe at a minimum dose of 2000 mg/kg, which is recommended for safety studies of non-toxic compounds. The total duration of observation of the animals was 14 days. In the first 24 hours the observation was carried out continuously. Evaluation of ‘acute’ toxicity at a single administration was carried out according to the GLP rules according to the following criteria: number of dead animals and terms of their death; general clinical picture of intoxication; changes in behavioral reactions. Results. After a single intragastric administration of the saliva substitute gel at a dose of experimental animal 2000 mg/kg, no cases of death were recorded. No clinical manifestations of intoxication and changes in animal behavior were also not observed. When studying the dynamics of body weight of experimental animals, it was found that during 14 days of the observation period there was a clear tendency to increase body weight of mice and rats of both sexes. Conclusion. No cases of death of experimental animals (mice, rats) were recorded during the toxicity evaluation in a single oral administration of moisturizing antixerostomy gel at a dose of 2000 mg/kg. The clinical manifestations of intoxication were not revealed. The research object (moisturizing antixerostomy gel) is a low-toxic substance that can be referred to the IV class of hazard- low-toxic chemicals.

16 October 2025 in Reviews on Clinical Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
VVValentina M. Vorobyova
Valentina M. Vorobyova
OMOlesya Nikolaevna Mazko
Olesya Nikolaevna Mazko
OSOksana Evgenievna Shishkina
Oksana Evgenievna Shishkina
STSvetlana Ivanovna Tokmakova
Svetlana Ivanovna Tokmakova
EMEvgeny Vladimirovich Mokrenko
Evgeny Vladimirovich Mokrenko
Xerostomia (dry mouth) is a common syndrome with multiple causes that tends to increase in prevalence as the population ages. The imitation of physiological saliva is a modern concept in the development of saliva replacement agents, with the gel dose form being considered optimal. This article provides a scientific rationale for the requirements and design of the pharmaceutical development of a hydrating dental gel for the symptomatic treatment of xerostomia in the context of import substitution. The information-retrieval stage of pharmaceutical development of artificial saliva is based on an understanding of the pathophysiology and etiology of xerostomia, as well as modern treatment approaches and knowledge of the composition, properties, and biological functions of human physiological saliva. The research stage of pharmaceutical development includes identifying potential molecules and compounds capable of mimicking the properties and functions of saliva, as well as formulating and improving the gel composition. An essential aspect is selecting a polymer combination with mucoadhesive properties. The search for a polymer composition includes cellulose derivatives, acrylic acid copolymers, alginates, hyaluronates, pectins, carrageenans, and fucoidans. Further expansion of structure-forming mucoadhesive polymers is possible through the use of recombinant mucins obtained by genetic engineering and plant extracts rich in polysaccharides that mimic mucin properties. Lysozyme, peroxidase, and lactoferrin, which are currently produced as bulk substances, as well as plant extracts, provide antimicrobial effects of artificial saliva. Buffering properties are maintained by potassium, sodium, and calcium bicarbonates and phosphates. Calcium lactate and fluorides impart remineralizing properties. The formulation of saliva substitutes includes organoleptic corrigents and preservatives. Selection criteria for compositions include quality parameters, biopharmaceutical performance, and antimicrobial and antioxidant characteristics of the saliva substitute. The proposed packaging for the hydrating dental gel includes 10–30 mL tubes, single-use stick packs, or strip packaging. The standardization stage involves modifying and validating analytical procedures specific to the composition, conducting stability tests, determining shelf life, and developing the process flowchart and regulatory documentation drafts. The composition and functions of salivary gland secretions serve as the foundation for defining the requirements and characteristics of the hydrating dental gel intended for pharmaceutical development. The optimal formulation is sought among combinations of mucoadhesive polymers with compounds exhibiting antimicrobial and remineralizing activity. Scientific data were analyzed and organized into a unified design framework for the pharmaceutical development of a hydrating dental gel for xerostomia therapy, comprising information-retrieval, research, and standardization stages. This design framework can be applied in research laboratories and educational institutions to train pharmaceutical industry professionals.